Eli Lilly's (LLY) LIBRETTO-001 Phase 1/2 trial of Selpercatinib (LOXO-292) shows a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Don’t see a project related to the catalyst you care about?